Agar micro-spheres produced by transacylation allow the encapsulation of fragile retinol.
This technology ensures that the micro-spheres reach the epidermis, where they are progressively opened by the activity of many different skin enzymes and gradually release retinol. This slow membrane digestion leads to a slow release of encapsulated retinol for better bioavailability, efficacy, and less irritation. The retinol thus contacts the skin and diffuses throughout the day. The modified release kinetics assured by encapsulation make them bio-compatible and hypo-allergen.